Michael Ragosta headshot
MR

Michael Ragosta

Professor
Unit: School of Medicine
Department: Department of Medicine, Cardiovascular Medicine
Office location and address
Heart and Vascular Center
1215 Lee St
Charlottesville, Virginia 22903
Education
MD, Medicine, Brown University
Fellowship, Cardiology, University of Virginia
Fellowship, Interventional Cardiology, University of Virginia
Residency, Internal Medicine, Yale New Haven Hospitals
Biography

Michael Ragosta, M.D., is board certified in internal medicine, cardiovascular diseases and interventional cardiology. He specializes in interventional cardiology, heart valve disease, general cardiology and peripheral arterial disease.

Dr. Ragosta has been principal investigator or co-principal investigator on 10 clinical trials involving myocardial viability, coronary collateral circulation, coronary flow reserve, fractional flow reserve and myocardial contrast echocardiography. He has shared his research and experience through more than 40 invited lectures or visiting professorships and by authoring or co-authoring more than 120 peer-reviewed journal publications, book chapters and scientific abstracts. Dr. Ragosta is Medical Director for Interventional Cardiology at UVA.

MD-INMD-CV A post-approval study of the Medtronic Resolute Onyx¿ Zotarolimus-Eluting Coronary Stent System
Source: Medtronic Vascular, Inc.
April 25, 2017 – August 08, 2025
MD-INMD-CV-MR8B-BIOTRONIX-BIOF Clinical Protocol for the BIOFLOW-V Study
Source: BIOTRONIK Inc.
April 28, 2015 – April 27, 2025
Early Feasibility Study of the AccuCinch® Ventriculoplasty
Source: Ancora Heart, Inc.
November 14, 2018 – July 30, 2024
Early Feasibility Study of the AccuCinch® Ventricular Repair System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
Source: Ancora Heart, Inc.
November 07, 2018 – July 30, 2024
Early Feasibility Study of the AccuCinch® Ventriculoplasty System
Source: Ancora Heart, Inc.
October 03, 2018 – July 30, 2024
MD-INMD-CV Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial
Source: Leland Stanford Junior University, The
April 24, 2015 – July 01, 2024
CAD Registry Protocol - Protocol T6-0011
Source: TALOSIX, LLC
February 24, 2021 – February 23, 2024
MD-INMD-CV-COMPLETE M1
Source: Hamilton Health Sciences Corporation
January 08, 2014 – January 07, 2024
BIOTRONIK-A Prospective Multicenter Study to Confirm the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - VII
Source: BIOTRONIK Inc.
March 09, 2020 – March 08, 2023
MD-INMD-CV CardiacAssist TandemHeart Theme Registry
Source: CardiacAssist, Inc.
April 30, 2015 – December 31, 2022
The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study
Source: Svelte Medical Systems, Inc.
October 26, 2017 – October 25, 2022
MD-INMD-CV-MR8B-OPTIMUM
Source: Saint Luke’s Hospital of Kansas City
April 12, 2017 – April 11, 2022
Surgical Implantation of TRAnscatheter vaLve in native mitral annular calcification (SITRAL) study
Source: Baylor Research Institute
October 20, 2017 – March 31, 2022
Onyx ONE Clear Study: A Single Arm Study with Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients who are considered One-Month Clear
Source: Medtronic Inc.
November 01, 2018 – March 08, 2022
The PIONEER III Trial: A Prospective Multicenter Global Randomized Controlled Trial Assessing the Safety and Efficacy of the BuMA Supreme¿ Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients...
Source: Nova Vascular LLC
December 21, 2017 – December 20, 2021
PRECISION GRX Registry Protocol - A Multicenter Post-Market Registry for the Evaluation of the CorPath® GRX System Effectiveness in Percutaneous Coronary Interventions
Source: Corindus, Inc.
November 08, 2017 – November 07, 2021
Hybrid Coronary Revascularization Trial- DCC
Source: Icahn School of Medicine at Mount Sinai
July 01, 2017 – June 30, 2021
MD-INMD-CV317-EXCEL Evaluation of XIENCEPRIME or XIENCE V vs Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization
Source: Abbott Cardiovascular Systems, Inc
March 22, 2012 – February 28, 2021
Resolute Integrity
Source: Medtronic Vascular, Inc.
October 03, 2012 – August 31, 2020
MD-INMD-CV-PRECISION Registry Protocol - A Multicenter Post-Market Registry for the Evaluation of the CorPath 200 System Effectiveness in Percutaneous Coronary Interventions
Source: Corindus, Inc.
September 16, 2015 – September 15, 2017
MD-INMD Janssen Research & Development - Ph.3b
Source: Janssen Scientific Affairs, L.L.C.
November 07, 2013 – December 31, 2016
DAPT Study
Source: Harvard Clinical Research Institute
October 15, 2009 – October 15, 2015
The TRANSLATE-ACS Study
Source: Eli Lilly USA, LLC
May 01, 2010 – May 01, 2015
MD-INMD Abbott Fund Cardiovascular Fellowship Grant 2013
Source: Abbott Fund
July 01, 2013 – December 31, 2014
MD-INMD Xience V USA Post Approval Study
Source: Abbott Cardiovascular Systems, Inc
August 07, 2008 – November 06, 2014
MD-INMD-CV Interventional Cardiology Fellowship Grant
Source: Boston Scientific Corporation
July 01, 2013 – June 30, 2014
A Comparison of Platelet Inhibition Following a Prasugrel 60mg or Prasugrel 30mg Loading Dose With or Without Pretreatment with a Clopidogrel Loading Dose in Acute Coronary Syndrome Subjects to Undergo Percutaneous Coronary Intervention
Source: St. Jude Medical, Cardiology Division, Inc.
October 22, 2010 – March 31, 2014
MD-INMD "Triplet" Platelet inhibition following Prasugrel 60 mg or 30 mg is ACS Pts
Source: Lilly USA, LLC
April 27, 2010 – February 20, 2014
MD-INMD Abbott Fund Cardiovascular Fellowship Grant
Source: Abbott Labs.
June 11, 2012 – June 30, 2013
Protocol D356IC00001 Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg
Source: AstraZeneca
March 14, 2008 – March 13, 2013

2011-2018 Best Doctors in America® List